Abstract
An obstacle confronting gene therapy in stem cells is transcriptional silencing of the vector. Here, we discuss recent data indicating that oncoretrovirus and lentivirus vectors are silenced by multiple epigenetic pathways that result in DNA methylation and histone modifications. Both vector types can be variegated in stem cells and expression is often extinguished during differentiation. We propose a novel model of retrovirus silencing in which epigenetic pathways compete to recruit histone deacetylases, de novo methyltransferases, histone H1 and MeCP2 to the provirus. These chromatin modifications may act in concert with heterochromatin at or near the integration site to establish silencing or variegation respectively. Retrovirus vector designs for stem cells should delete virus silencer elements, incorporate strong positive regulatory elements and insulators, and avoid non-mammalian reporter genes. In addition, cancer stem cells that continually repopulate a growing tumour may share silencing pathways with normal stem cells. Ultimately, optimized vector designs may prove to be valuable tools for gene therapy of both normal and cancer stem cells.
Keywords: stem cells, heterochromatin, non-mammalian reporter genes
Current Gene Therapy
Title: Retrovirus Silencing and Vector Design: Relevance to Normal and Cancer Stem Cells?
Volume: 5 Issue: 4
Author(s): James Ellis and Shuyuan Yao
Affiliation:
Keywords: stem cells, heterochromatin, non-mammalian reporter genes
Abstract: An obstacle confronting gene therapy in stem cells is transcriptional silencing of the vector. Here, we discuss recent data indicating that oncoretrovirus and lentivirus vectors are silenced by multiple epigenetic pathways that result in DNA methylation and histone modifications. Both vector types can be variegated in stem cells and expression is often extinguished during differentiation. We propose a novel model of retrovirus silencing in which epigenetic pathways compete to recruit histone deacetylases, de novo methyltransferases, histone H1 and MeCP2 to the provirus. These chromatin modifications may act in concert with heterochromatin at or near the integration site to establish silencing or variegation respectively. Retrovirus vector designs for stem cells should delete virus silencer elements, incorporate strong positive regulatory elements and insulators, and avoid non-mammalian reporter genes. In addition, cancer stem cells that continually repopulate a growing tumour may share silencing pathways with normal stem cells. Ultimately, optimized vector designs may prove to be valuable tools for gene therapy of both normal and cancer stem cells.
Export Options
About this article
Cite this article as:
Ellis James and Yao Shuyuan, Retrovirus Silencing and Vector Design: Relevance to Normal and Cancer Stem Cells?, Current Gene Therapy 2005; 5 (4) . https://dx.doi.org/10.2174/1566523054546233
DOI https://dx.doi.org/10.2174/1566523054546233 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lectin Microarrays: A Powerful Tool for Glycan-Based Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Graphical Abstracts:
Anti-Cancer Agents in Medicinal Chemistry Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets Pancreatic Cancer Metastasis: Are we being Pre-EMTed?
Current Pharmaceutical Design Potential Application of Biliverdin Reductase and its Fragments to Modulate insulin/IGF-1/MAPK/PI3-K Signaling Pathways in Therapeutic Settings
Current Drug Targets Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors
Current Neuropharmacology CD4+CD25+ T Regulatory Cells and TGF-β in Mucosal Immune System: The Good and the Bad
Current Medicinal Chemistry Poloxamer 188 (P188), A Potential Polymeric Protective Agent for Central Nervous System Disorders: A Systematic Review
Current Neuropharmacology Stroke Induced Immunodepression Syndrome: From Bench to Bedside
Current Molecular Medicine “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs
Current Cancer Therapy Reviews Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry Graphical Abstracts:
Current Radiopharmaceuticals Tumor Thermal Ablation Enhancement by Micromaterials
Current Drug Delivery Anti Cancer Activity on Graviola, an Exciting Medicinal Plant Extract vs Various Cancer Cell Lines and a Detailed Computational Study on its Potent Anti-Cancerous Leads
Current Topics in Medicinal Chemistry Extracellular Citrate in Health and Disease
Current Molecular Medicine Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry In-Vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models
Letters in Drug Design & Discovery Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives
Current Cancer Therapy Reviews